US regulators allow remdesivir for hospitalised

Gilead said in a statement that the expanded emergency use was based on results of a recent federal study of hospitalized patients with different levels of severity, plus a Gilead study published a week ago. Gilead's study found that among hospitalized patients with moderate COVID-19, those getting remdesivir were 65% more likely to improve after a five-day treatment course than those just getting standard care.

U.S. regulators are now allowing the use of experimental antiviral drug remdesivir for all patients hospitalized with COVID-19, drugmaker Gilead Sciences said Friday. It said the Food and Drug Administration has expanded its emergency use authorization, which lets doctors administer the IV drug during the pandemic. Until now, that was limited to patients with severe COVID-19.

Foster City, California-based Gilead applied to the FDA on Aug. 10 for formal approval of remdesivir, to be sold under the brand name Veklury. Gilead said in a statement that the expanded emergency use was based on results of a recent federal study of hospitalized patients with different levels of severity, plus a Gilead study published a week ago.

Gilead's study found that among hospitalized patients with moderate COVID-19, those getting remdesivir were 65% more likely to improve after a five-day treatment course than those just getting standard care. Remdesivir previously was shown to shorten treatment by about four days for hospitalized patients with severe disease, compared with those getting standard supportive care.